Abstract:Pharmacological evidence indicated a functional interaction between neuropeptide FF (NPFF) and cannabinoid systems, and the cannabinoids combined with the NPFF receptor agonist neuropeptide VF (NPVF) produced antinociception without tolerance. In the present study, VF-13, a chimeric peptide containing the pharmacophores of the endogenous cannabinoid peptide VD-hemopressin(α) (VD-Hpα) and NPVF, was synthesized and pharmacologically evaluated. In vitro, VF-13 significantly upregulated the phosphorylated level of extracellular signal-regulated kinase 1/2 (ERK1/2) in CHO cells stably expressing CB1 receptors and inhibited forskolin-induced cAMP accumulation in HEK293 cells stably expressing NPFF1 or NPFF2 receptors. Moreover, VF-13 induced neurite outgrowth in Neuro 2A cells via CB1 and NPFF receptors. These results suggest that VF-13 exhibits multifunctional agonism at CB1, NPFF1 and NPFF2 receptors in vitro. Interestingly, intracerebroventricular VF-13 produced dose-dependent antinociception in mouse models of tail-flick and carrageenan-induced inflammatory pain via the TRPV1 receptor. In contrast, the reference compound (m)VD-Hpα-NH2 induced CB1 receptor-mediated supraspinal antinociception. Additionally, subcutaneous injection of (m)VD-Hpα-NH2 and VF-13 produced significant antinociception in carrageenan-induced inflammatory pain model. In the tetrad assay, our data demonstrated that VF-13 elicited hypothermia, but not catalepsy and hypoactivity after intracerebroventricular injection. Notably, VF-13 produced non-tolerance forming antinociception over 6 days treatment in both acute and inflammatory pain models. Furthermore, VF-13 had no apparent effects on gastrointestinal transit, pentobarbitone-induced sedation, food intake, and motor coordination at the supraspinal level. In summary, VF-13, a novel chimeric peptide of VD-Hpα and NPVF, produced non-tolerance forming antinociception in preclinical pain models with reduced cannabinoid-related side effects.

In vivo inhibition of neuropeptide FF agonism by BIBP3226, an NPY Y1 receptor antagonist.

BIBP 3226 inhibition of nicotinic receptor mediated chromaffin cell secretion.

Neuropeptide-Y Inhibition of Nicotinic Receptor-Mediated Chromaffin Cell Secretion

Inhibition of Neuropeptide FF (Npff)-Induced Hypothermia and Anti-Morphine Analgesia by RF9, a New Selective NPFF Receptors Antagonist

Identification of an NPY-Y1 Receptor Subtype in Bovine Chromaffin Cells

BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist

Neuropeptide Y secretion from bovine chromaffin cells inhibits cyclic amp accumulation

Neuropeptide FF Receptors Exert Contractile Activity Via Inhibition of Nitric Oxide Release in the Mouse Distal Colon.

Effects of Neuropeptide FF and Related Peptides on the Antinociceptive Activities of VD-hemopressin(α) in Naive and Cannabinoid-Tolerant Mice.

Central administration of neuropeptide FF and related peptides attenuate systemic morphine analgesia in mice.

Peripheral and Central Sites of Action for Anti-Allodynic Activity Induced by the Bifunctional Opioid/npff Receptors Agonist BN-9 in Inflammatory Pain Model

In Vitro and in Vivo Studies of Dansylated Compounds, the Putative Agonists and Antagonists on Neuropeptide FF Receptors

Effects of Neuropeptide Ff System on Cb1 and Cb2 Receptors Mediated Antinociception in Mice

BN-9, a Chimeric Peptide with Mixed Opioid and Neuropeptide FF Receptor Agonistic Properties, Produces Nontolerance-Forming Antinociception in Mice.

Pressor and Tachycardic Responses to Intrathecal Administration of Neuropeptide FF in Anesthetized Rats

Neuropeptide Ff Attenuates the Acquisition and the Expression of Conditioned Place Aversion to Endomorphin-2 in Mice

Neuropeptide FF receptors antagonist, RF9, attenuates opioid-evoked hypothermia in mice.

The Anti-Inflammatory Potential of Neuropeptide FF in Vitro and in Vivo.

Anti-Nociceptive Role of Neuropeptide Y in the Nucleus Accumbens in Rats with Inflammation, an Effect Modulated by Mu- and Kappa-Opioid Receptors

Opposite Effects of Neuropeptide FF on Central Antinociception Induced by Endomorphin-1 and Endomorphin-2 in Mice.

VF-13, a chimeric peptide of VD-hemopressin(α) and neuropeptide VF, produces potent antinociception with reduced cannabinoid-related side effects